The Fitzrovia Centre®

How it works


The scalp bears an average of 110,000 hair follicles, which are growing and falling out on a day to day basis. When the balance between growing hair and falling ones is out of balance then hair loss commences leading to baldness.
The hair cycle is made of three phases:

  1. Anagen phase during which the hair
    is growing (± 3 years)
  2. Catagen phase also called the
    transition phase (± 3 weeks)
  3. Telogen phase during which the hair
    is dying and falling (± 3 months), which
    is followed by the anagen phase again.



  • 40% of men will have noticeable hair loss (alopecia) by age 35. This number reaches 65% by 60 years of age.
  • Women are also deeply impacted by hair loss, where 50 to 75% suffer noticeable hair loss by age 65.

Hair loss can be devastating to one’s self image and emotional well-being

When suffering from hair loss, the telogen phase is prolonged, and the transition to the anagen phase becomes more difficult. Hair becomes thinner and the percentage of hair transitioning to the telogen phase continues to increase.

However, the problem comes from the fact that the hair follicle stem cells (also called ORSc) located in the bulge along the hair, are less productive, and less adapted to improve the quality of the matrix (made of keratinocytes) supporting the hair follicle growth. Furthermore, the fibroblasts located in the dermal papilla (also called HFDPc) are less efficient in communicating with the stem cells, meaning that the matrix will not be renewed as it used to.

Initiating the anagen phase becomes slower, and hair loss becomes more of an issue


The Fitzrovia Centres Hair Loss Treatments use a newly developed active ingredient called REDENSYL®, which is made up of patented molecules.

Redensyl is the newest breakthrough against hair loss and the best alternative to hair transplantation. It is the first hair care cosmetic active ingredient based on regenerative medicine researches that gives this level of results.

Two patented molecules uniquely target both the hair follicle stem cells and dermal papilla fibroplasts for improved results.

The two patented molecules — DHQG and EGCG2 — help hair loss and the reactivation of hair growth by targeting hair follicle stems cells, reactivating the proliferation of ORSc stem cells, protecting them from apoptosis, maintaining their differentiation properties and helping to activate the metabolism of dermal papillary fibroblasts.

Redensyl is a synergistic blend of 4 molecules that reactivates the bulge stem cells (ORSc) to favor hair growth.

Redensyl is a synergistic blend of 4 molecules that reactivates the bulge stem cells (ORSc) to favor hair growth.

  • Dihydroquercetin-glucoside (DHQG): a stabilized polyphenol, which activates the division of hair follicle stem cells, while maintaining their differentiation properties. It protects stem cells from apoptosis (BCL2 activation), and drives them towards the anagen cycle (β-catenin activation), while boosting the metabolism of dermal papilla fibroblasts.
  • EGCG-glucoside (EGCG2): a stabilized EGCG derivative used to reduce the typical inflamed state of alopecic scalp (reduction of IL-8), and capture free radicals.
  • Glycine: a major constituent of hair proteins, mainly keratin associated proteins (KAP), which support hair growth.
  • Zinc: a vital co-factor for numerous enzymes, allowing the incorporation of cystin in keratin for a stronger hair shaft.

A Clinical assessment of Redensyl at 3% on volunteers produced outstanding results for Redensyl.

In 3 months, the results included:

  • An average increase of +10,200 hair follicles
  • 85% of the volunteers had significant and visible success
  • +9% increase of new growing hair
  • 17% reduction of falling hair

Join our mailing list
Item Added to Bag
Enter Checkout >